AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00967187
Drug: bevirimat dimeglumine
RxNorm normalized name: Fosaprepitant Dimeglumine
DrugBank: Bevirimat (DB06581)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with MPC-4326, 300 mg monotherapy for 14 days. Once the Day 15 viral load results become available patients who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
Trial: NCT01543269
Drug: ZYT1
RxNorm normalized name: Zolpidem Tartrate
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dose of ZYT1 in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
Trial: NCT01723904
Drug: Rotigotine
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of Rotigotine up to 8 mg/24 h patches for 24 hours.
Trial: NCT02687334
Drug: 100% Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We will investigate the changes of cerebral oxygenation during anesthesia induction of standard general anesthesia with 100% oxygen
Trial: NCT00622635
Drug: Indacaterol 300 μg
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indacaterol 300 μg was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
Trial: NCT00622635
Drug: Placebo to indacaterol
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo to indacaterol was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
Trial: NCT00622635
Drug: Salmeterol 50 μg
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Salmeterol 50 μg was provided in powder filled capsules with a multi-dose dry-powder inhaler (MDDPI).
Trial: NCT05090449
Drug: Losartan (COZZAR®)
RxNorm normalized name: losartan Oral Tablet [Cozaar]
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan potassium 100 mg tablet, a product of Schering-Plough, S.A. C.V.
Trial: NCT01167946
Drug: methylprednisolone sodium succinate
RxNorm normalized name: Methylprednisolone Sodium Succinate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
Trial: NCT01167946
Drug: methylprednisolone sodium succinate
RxNorm normalized name: Methylprednisolone Sodium Succinate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group B will receive 2 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
Trial: NCT01167946
Drug: methylprednisolone sodium succinate
RxNorm normalized name: Methylprednisolone Sodium Succinate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group C will receive 3 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
Trial: NCT03965052
Drug: PRO 179
RxNorm normalized name: Climara Pro
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Generic name: Travoprost~* Distinctive denomination: Bristrio® (PRO-179)~* Active principles: Travoprost 0.004%.~* Pharmaceutical form: Ophthalmic solution~* Presentation: multi-dose dropper bottle, 2.5 milliliters.~* Prepared by: Sophia Laboratories, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene.
Trial: NCT00761059
Drug: Aqua
RxNorm normalized name: AQUA
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The oral application of 0,3 ml/kg Aqua 3 minutes before nasopharyngeal suctioning
Trial: NCT02545907
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lyophilized carfilzomib for injection reconstituted with water to a final concentration of 2 mg/mL.
Trial: NCT02545907
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50mg capsule.
Trial: NCT02545907
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2mg tablet.
Trial: NCT03933293
Drug: AK102
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 450mg, Q4W, subcutaneous injection
Trial: NCT03933293
Drug: Statins
RxNorm normalized name: Endostatins
DrugBank: Endostatin (DB06423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering therapies
Trial: NCT03933293
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lipid-lowering therapies
Trial: NCT00240422
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00240422
Drug: Ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00271336
Drug: Pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03970109
Drug: ANS-6637
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg (given as 2 x 100 mg tablet) and 600 mg (given as 2 x 300 mg tablet) once a day
Trial: NCT01313572
Drug: Apadenoson SPECT-MPI
RxNorm normalized name: spelt seed extract
DrugBank: Apadenoson (DB05009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apadenoson single bolus IV injection 100 or 150 ug
Trial: NCT03221257
Drug: Pirfenidone (PFD)
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive PFD titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
Trial: NCT03221257
Drug: Mycophenolate Mofetil (MMF)
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive MMF titrated up to a target dose of 1500 mg taken twice daily as tolerated (4-step titration occurring at monthly intervals).
Trial: NCT02207829
Drug: Umeclidinium
RxNorm normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Umeclidinium 62.5 mcg once daily in the morning via nDPI
Trial: NCT02207829
Drug: Umeclidinium matching placebo
RxNorm normalized name: Umeclidinium
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Umeclidinium matching placebo once daily in the morning via nDPI
Trial: NCT02207829
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 mcg once daily in the morning via HANDIHALER inhaler
Trial: NCT02207829
Drug: Tiotropium matching placebo
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium matching placebo once daily in the morning via HANDIHALER inhaler
Trial: NCT03519230
Drug: Pamiparib capsule
RxNorm normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg twice daily (BID), orally (per os-PO)
Trial: NCT02778204
Drug: Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg/kg oral solution as a single dose.
Trial: NCT02778204
Drug: Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg/kg oral solution given twice daily.
Trial: NCT04666441
Drug: REGN10933+REGN10987 combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV or SC single dose
Trial: NCT00298038
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01823393
Drug: NaCl
RxNorm normalized name: NaCl
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: valvuloplasty is performed without heparin (placebo injection)
Trial: NCT00389818
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg PO Days 1-5 of each cycle
Trial: NCT00389818
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m2 IV Day 1 (2.0 mg maximum) of each cycle
Trial: NCT00499369
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01626976
Drug: PF-06282999
RxNorm normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, doses range from 20 to 200 mg, single dose
Trial: NCT01626976
Drug: PF-06282999
RxNorm normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylcellulose suspension, doses range 125 to 500 mg, single dose
Trial: NCT01626976
Drug: PF-06282999
RxNorm normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylcellulose or simethicone suspension, doses range 200 to 500 mg, single dose
Trial: NCT01626976
Drug: PF-06282999
RxNorm normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylcellulose or simethicone suspension, 500 mg dose, single dose
Trial: NCT01626976
Drug: PF-06282999
RxNorm normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone or methylcellulose suspension, up to 1500 mg, single dose
Trial: NCT05166005
Drug: vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week or low dose vitamin D (2,000 IU daily).
Trial: NCT04274738
Drug: Mavorixafor
RxNorm normalized name: Mavorixafor
DrugBank: Mavorixafor (DB05501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavorixafor capsules will be administered per dose and schedule specified in the arm.
Trial: NCT04274738
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib capsules will be administered per dose and schedule specified in the arm.
Trial: NCT03787849
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction. After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.
Trial: NCT03787849
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% until lost of conscience and peripheral vein puncture. After that, sevoflurane will be turned off and its clearance will be analyzed through gas analyzer monitor. From here, anesthesia will be maintained as total venous with continuous propofol infusion 100 mcg.kg.min-1 until completion of the procedure.
Trial: NCT00320281
Drug: botulinum toxin A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Injection of BTXA into cervical and upper back muscles based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit.Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
Trial: NCT04498897
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate
Trial: NCT04498897
Drug: Acamprosate
RxNorm normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate
Trial: NCT03258476
Drug: Guanfacine Extended Release
RxNorm normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intuniv (guanfacine) is a prescription medicine used to treat attention deficit hyperactivity disorder (ADHD) in children who are at least 6 years old. An open-label trail of guanfacine extended release (GXR 1-4 mg/daily; Intuniv™) suggested benefits in improving behavioral and emotional regulation in children and adolescents with symptoms of traumatic stress. However, to date no controlled clinical trial has been completed assessing the effects of GXR on traumatic stress symptoms in youths
Trial: NCT02412267
Drug: O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumab in combination with ICE (Ifosfamide, Carboplatin, Etoposide) are given to subjects according to protocol schedule
Trial: NCT01055392
Drug: Lithium Carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lithium carbonate tablets, 150 mg to 450 mg (target serum lithium level 0.25 mEq/L - 0.5 mEq/L), divided in two doses, two years.
Trial: NCT02293005
Drug: Alisertib
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg twice a day on Days 1-7 of each 21-day study cycle.
Trial: NCT02642913
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02642913
Drug: Enzalutamide with Sorafenib
RxNorm normalized name: Enzalutamide
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02039531
Drug: Hyaluronic Acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04011475
Drug: Tiotropium + Olodaterol
RxNorm normalized name: olodaterol / tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiolto®
Trial: NCT04011475
Drug: LAMA
RxNorm normalized name: Alamag
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aclidinium bromide, glycopyrronium, tiotropium, umeclidinium
Trial: NCT00752505
Drug: Esreboxetine
RxNorm normalized name: Esreboxetine
DrugBank: Esreboxetine (DB12395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
Trial: NCT00045994
Drug: ALT-711
RxNorm normalized name: ALT-801
DrugBank: ALT-801 (DB15386)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00147147
Drug: Gastrectomy+ chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02329405
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00126048
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg tablet
Trial: NCT02192684
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 45 mg daily Insulin sensitizing
Trial: NCT01607905
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants in this study will receive selinexor orally at dose levels specified for their respective dose cohorts. Dosing will begin at 3 mg/m\^2 twice a week and will escalate until the MTD or RP2D is determined. Cycles will be repeated in 4-week (28 days for schedule 1 to 7) and 3-week (21 days for schedule 8) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
Trial: NCT02602288
Drug: Nicotine polacrilex
RxNorm normalized name: Nicotine Polacrilex
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Over the counter nicotine replacement therapy in gum or lozenge form.
Trial: NCT00185133
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00185133
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01429545
Drug: Atosiban
RxNorm normalized name: atosiban
DrugBank: Atosiban (DB09059)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.
Trial: NCT01429545
Drug: Atosiban and nifedipine
RxNorm normalized name: atosiban
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This group were given simultaneously as follows:Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.Nifedipine was given in the dose of 10 mg orally every 15 min till uterine quiescence was achieved (\<4 contractions/hr). Maximum dose was 40 mg in the first hour then maintenance dose of 10 mg every 4-6 h for 48 hrs was given.
Trial: NCT01621373
Drug: propofol administration
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single IV bolus propofol start at 1 mg/kg. Dose will be adapted based on predefined scoring systems with +/-0.5 mg/kg.
Trial: NCT00000435
Drug: dnaJ peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dnaJP1 was taken in pill form at 25mg/day for 6 months
Trial: NCT01105533
Drug: PF-00337210
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous
Trial: NCT01105533
Drug: PF-00337210
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg Capsule Once Daily (Dose Escalation) Continuous
Trial: NCT01105533
Drug: PF-00337210
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2mg Capsule Once Daily (Dose Escalation) Continuous
Trial: NCT01105533
Drug: PF-00337210
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4mg Capsule Once Daily (Dose Escalation) Continuous
Trial: NCT01105533
Drug: PF-00337210
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6mg Capsule Once Daily (Dose Escalation) Continuous
Trial: NCT01105533
Drug: PF-00337210
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9mg Capsule Once Daily (Dose Escalation) Continuous
Trial: NCT01105533
Drug: PF-00337210
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8mg Capsule Once Daily (Dose Escalation) Continuous
Trial: NCT01105533
Drug: PF-00337210
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4mg Capsule Twice Daily (Dose Escalation) Continuous
Trial: NCT01105533
Drug: PF-00337210
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6mg Capsule Twice Daily (Dose Escalation) Continuous
Trial: NCT01105533
Drug: PF-00337210
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6mg Capsule Twice Daily (Dose Expansion) Continuous
Trial: NCT01917045
Drug: Sufentanil (R30730, brand name Sufenta) + Morphine
RxNorm normalized name: sufentanil Injection [Sufenta]
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sufentanil 0.5ug/ml+morphine 0.25mg/ml
Trial: NCT01917045
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: morphine 0. 5mg/ml
Trial: NCT00467181
Drug: Fenoldopam
RxNorm normalized name: Fenoldopam
DrugBank: Fenoldopam (DB00800)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02448303
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02448303
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00630877
Drug: Niacin extended-release (NER)
RxNorm normalized name: niacin Extended Release Oral Capsule
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered once daily for 6 weeks; titrated to a maximum dose of 2000 mg